Los Angeles County's device, biotech and contract research base is dispersed rather than clustered: the Pasadena and foothill corridor, the Westside and El Segundo, the South Bay and Torrance, and the research institutions that seed all of it. That dispersion is the planning fact. Your hiring radius is a commute rather than a county, and many of your candidates are leaving university and hospital retirement plans that are hard to compare against.
Where do medical device, biotech and scientific R&D cluster in Los Angeles County?
Start with what generates the companies, because in this county that is more legible than where they land. UCLA in Westwood, Caltech in Pasadena and the Jet Propulsion Laboratory it manages, City of Hope's medical center and research institute in Duarte, the USC health sciences campus east of downtown, Cedars-Sinai, and the Lundquist Institute on the Harbor-UCLA campus in West Carson. These produce principal investigators, postdocs, technology licences and spinouts, and they are also where a great many of your future employees are working right now.
Where the companies actually sit is a different map. The foothill corridor along the 210 — Pasadena, Monrovia, Duarte, Arcadia — carries research-stage biotech, diagnostics and laboratory-services companies close to Caltech and City of Hope. The Westside and the coast carry a blend of device, diagnostics and digital health that shades into the technology economy: Culver City, Playa Vista, Santa Monica and El Segundo, where cell therapy and biologics manufacturing has taken large industrial space. The South Bay and Torrance hold device manufacturing and contract research on the same industrial base the aerospace supply chain uses, and the San Fernando Valley has an older device manufacturing presence that predates most of it.
The scatter is the defining feature and it has consequences. There is no equivalent here of a single business park where a career can be spent moving between employers without changing the commute. A company in Monrovia and a company in El Segundo are in the same county and the same sector, and functionally in different labor markets, because nobody drives that at five in the afternoon. Your candidate pool is drawn by a radius, not a county line, and that raises what a benefits package has to do.
What does CalSavers require of a LA County medical device, biotech and scientific R&D employer?
The same thing it requires everywhere in California, and every deadline has already passed. If you have one or more W-2 employees, you must either register with CalSavers or sponsor a qualified retirement plan and certify an exemption.
| Employees | Deadline | Where you stand in 2026 |
|---|---|---|
| 1–4 | 31 December 2025 | First notices are going out to this group now |
| 5–49 | 30 June 2022 | Confirm you are on file; watch for FTB notices |
| 50–99 | 30 June 2021 | Confirm, and revisit whether a 401(k) now fits better |
| 100+ | 30 September 2020 | Review plan design and fiduciary coverage |
Registration is free and the employer never touches the money. The exemption route is the one most medical device, biotech and scientific R&D miss: sponsoring your own plan does not exempt you automatically — you have to certify it, and the certification repeats.
What does ignoring it cost?
$250 per eligible employee at 90 days past notice, another $500 at 180 days, then $500 per employee every year you stay non-compliant (the full mechanics). For a 26-person operation that is $19,500 in the first cycle and $13,000 a year after — more than a plan would cost. If a notice has already landed, the 90-day FTB appeal window closes permanently at the final notice: read this before you file anything.
A notice already arrived?
Fifteen minutes on the phone and you will know exactly where you stand and what to do this week. No charge, no obligation, no product pitch.
What makes this industry harder than the mandate assumes?
The law treats every employer alike. The payroll underneath does not cooperate:
- The plan was adopted cheaply and early and nobody has revisited its fees, fund lineup or fiduciary documentation since the first close.
- Equity compensation absorbs every benefits conversation the board has, so the qualified plan is treated as an administrative item rather than a recruiting instrument.
- Candidates arrive from universities, research institutes and hospital systems with employer-funded retirement arrangements that a young company's plan is measured against.
- Headcount moves in steps at financing and clinical milestones, which crosses testing and audit thresholds without anyone forecasting it.
- Sites scattered from Pasadena to the South Bay mean one company can run two payroll setups and two benefits realities without noticing.
Typical headcount in this sector runs 10-250 employees, and roughly 60-75% of firms (est.) currently sponsor a plan of any kind — which is why the mandate lands here harder than in sectors that were already covered.
What plan design actually works?
The chassis is a safe harbor 401(k), because in a company where a few founders and senior scientists earn far more than a bench-heavy staff, the alternative is having their deferrals limited every year by what everyone else happens to save. Add a Roth deferral source. In this sector a substantial share of the staff sit above the Roth IRA income limits — roughly $168,000 single or $252,000 joint — and inside the plan they can make Roth contributions anyway, up to the $24,500 deferral limit rather than the $7,500 the state programme allows. That single design choice is worth more to a Los Angeles device company's census than most of what gets discussed at board level.
Two further points specific to a dispersed, fast-growing county sector. First, if you run multiple sites — a lab in Pasadena and manufacturing in the South Bay is a common shape — keep one plan and one payroll feed, because two payroll systems remitting to one plan is the most reliable way to generate late deposits. Second, watch the audit threshold: since the 2023 filing rules the large-plan audit requirement is counted on participants with account balances rather than everyone eligible, so a company hiring fast can manage when it crosses. And if the plan you already have was placed by whoever sold you payroll at Series A, benchmark what it costs before you defend it.
The SECURE 2.0 startup credits often cover most of the first three years of administration for employers under 50 staff — the formula, worked honestly. And if after the arithmetic CalSavers is genuinely the cheaper answer for your shop, we will tell you so and you can register and be done: the full comparison · run your own numbers.
| CalSavers | 401(k) | |
|---|---|---|
| Employee deferral limit (2026) | $7,500 | $24,500 |
| Employer match permitted | No — prohibited | Yes |
| Owner above the Roth income limits can participate | No | Yes |
| SECURE 2.0 startup credits | $0 | Up to $5,000/yr × 3 yrs |
| Named fiduciary available | No | Yes — 3(38) or 3(21) |
The LA County wrinkle
The wrinkle nobody warns Los Angeles founders about is who they are hiring away from. A large share of the technical staff a device or biotech company here wants — scientists, research associates, biostatisticians, regulatory and clinical people — are currently at a university, a research institute or a hospital system, and those employers run retirement arrangements built on a different model: employer-funded plans, 403(b) and 457(b) arrangements alongside them, and long institutional histories of contributing. We are not going to characterise any specific institution's plan, and neither should your recruiter. The point is structural. When a candidate leaves that world for a twenty-six person company whose 401(k) has no employer contribution, they are not comparing your match against another startup's match. They are comparing it against something that was never framed as a match at all, and the equity grant you are offering does not resolve the comparison on its own.
The second county-specific item is more mundane and gets missed at incorporation. Companies inside Los Angeles city limits — which includes Westwood, Playa Vista, Sylmar and everything else in the city's very long boundary — are subject to the city's gross-receipts business tax and its registration certificate, which pre-revenue and grant-funded companies routinely discover late. Pasadena, Monrovia, Culver City and the other independent cities each run their own licensing regime instead. It is not a retirement issue, but it is one more state and local obligation in the pile that the CalSavers notice lands on top of, and it explains why the notice gets filed rather than answered.
Los Angeles County has 88 incorporated cities and about 9.7 million residents, and the enforcement letters go out by employer, not by city — but which city you are in changes who your neighbours are, what your labor market looks like, and often what your local business tax and licensing burden already is. The city pages below go into that.
CalSavers compliance, city by city
Where medical device, biotech and scientific R&D concentrate in Los Angeles County:
- CalSavers for Los Angeles employers
- CalSavers for Pasadena employers
- CalSavers for Duarte employers
- CalSavers for Monrovia employers
- CalSavers for Culver City employers
- CalSavers for El Segundo employers
- CalSavers for Torrance employers
- CalSavers for West Carson employers
- CalSavers for Long Beach employers
- CalSavers for Woodland Hills employers
All Los Angeles County CalSavers guidance → · The medical device, biotech and scientific R&D plan guide, statewide → · The same industry in Orange County →
Our fees, published
No competing advisor page in this area publishes its fees. Here are ours.
| What | Fee |
|---|---|
| Investment management | 1.5% to 2.0% of assets per year; Advisers may set a rate below the standard schedule, as low as 0%, at their discretion — and whatever rate applies to you is disclosed in writing before you engage. Our Form ADV Part 2A, Item 5, states the fee as up to 2.00% of assets per year, subject to negotiation; the firm may waive all or part of it. Generally billed quarterly in arrears |
| Account minimum | No minimum account balance |
| Commissions and product fees | None — we are fee-only |
| Solicitor compensation | May be received or paid under disclosed arrangements |
| Initial conversation | Free, 15 minutes, no obligation |
Complete fee details in our Form ADV Part 2A, Item 5.
LA County medical device, biotech and scientific R&D questions
We hire out of UCLA, Caltech and City of Hope. What are candidates comparing us to?
Something structurally different from another startup's package, and we will not describe any particular institution's plan because those change and misstating one would be worse than useless. In general terms, large universities, research institutes and hospital systems tend to run mature retirement arrangements with meaningful employer funding, often alongside 403(b) and 457(b) options, and staff there rarely think of it as a "match". Someone leaving that for your company is taking a real step down in guaranteed retirement funding in exchange for equity and the work. The practical response is to be specific: name your employer contribution as a number, explain the vesting, and show the plan's costs. Vagueness reads as nothing.
We are grant-funded. Can employer retirement contributions be charged to the grant?
Fringe benefit costs, including employer retirement contributions, are generally treated as allowable costs under the federal uniform administrative requirements when they follow an established, consistently applied policy and are properly allocated — commonly through a negotiated or de minimis fringe rate rather than as an ad hoc line. The conditions are real and the details depend on your award terms and your accounting practice, so confirm it with your grants administrator and your CPA before you assume either way. What matters for design is sequencing: a contribution policy that is consistent and documented from the start is far easier to support than one introduced mid-award.
We have a lab in Pasadena and manufacturing in the South Bay. One plan or two?
One plan, almost always. Two plans for one employer means duplicated documents, duplicated filings, duplicated audits eventually, and coverage testing that has to be run across both anyway. What actually needs unifying is the payroll feed. The recurring failure in multi-site companies is that the two locations were set up in payroll at different times with different deferral codes and different pay frequencies, and deferrals from one site arrive late or at the wrong rate. That is an operational error with a correction procedure attached to it, and it is entirely avoidable by fixing the feed once.
Our current advisor is the firm that sold us the plan. Is that a problem?
It is not automatically a problem, but you should be able to answer three questions about them and most companies at your stage cannot. Are they a fiduciary to your plan in writing, and as a 3(38) or a 3(21)? How are they paid, by whom, and does any part of their compensation vary with which funds are in the lineup? What is the plan's total cost as a percentage of assets, including the expense ratios inside the funds? Those answers exist in documents you already have. We are fee-only and publish our fees at fees, which makes the second question easy to answer about us.
Do you actually work with medical device, biotech and scientific R&D in Los Angeles County?
Yes. Our office is at 12838 Rosecrans Ave in Norwalk — inside Los Angeles County, and about a 20-minute drive from most of Los Angeles County's business corridors. We meet at our office or at your place of business. Call (657) 571-2607. We are registered as an investment adviser in California.
¿Atienden en español?
Sí. Atendemos en español y nuestro material sobre CalSavers existe en español, escrito originalmente, no traducido por máquina.
A plan designed around medical device, biotech and scientific R&D in LA County — not around the average employer
We design around the census you actually have — turnover, seasonality, owner compensation and all. Fifteen minutes, no charge, and a straight answer either way.